Effect of Empiric Anti–Mycobacterium tuberculosis Therapy on Survival Among Human Immunodeficiency Virus–Infected Adults Admitted With Sepsis to a Regional Referral Hospital in Uganda
![Thumbnail](/xmlui/bitstream/handle/123456789/3711/Effect%20of%20Empiric%20Anti%e2%80%93Mycobacterium%20tuberculosis%20Therapy%20on%20Survival%20Among%20Human%20Immunodeficiency%20Virus%e2%80%93Infected%20Adults%20Admitted%20with%20Sepsis%20to%20a%20Regional%20Referral%20Hospital%20in%20Uganda.pdf.jpg?sequence=4&isAllowed=y)
View/ Open
Date
2019Author
Hazard, Riley H.
Kagina, Peninah
Kitayimbwa, Richard
Male, Keneth
McShane, Melissa
Mubiru, Dennis
Welikhe, Emma
Moore, Christopher C.
Abdallah, Amir
Metadata
Show full item recordAbstract
Background: Mycobacterium tuberculosis is the leading cause of bloodstream infection among human immunodeficiency virus (HIV)–infected patients with sepsis in sub-Saharan Africa and is associated with high mortality rates.
Methods: We conducted a retrospective study of HIV-infected adults with sepsis at the Mbarara Regional Referral Hospital in Uganda to measure the proportion who received antituberculosis therapy and to determine the relationship between antituberculosis therapy and 28-day survival. Results: Of the 149 patients evaluated, 74 (50%) had severe sepsis and 48 (32%) died. Of the 55 patients (37%) who received antituberculosis therapy, 19 (35%) died, compared with 29 of 94 (31%) who did not receive such therapy (odds ratio, 1.34; 95% confidence interval [CI], .56–3.18; P = .64). The 28-day survival rates did not differ significantly between these 2 groups (log-rank test, P = .21). Among the 74 patients with severe sepsis, 9 of 26 (35%) who received antituberculosis therapy died, versus 23 of 48 (48%) who did not receive such therapy (odds ratio, 0.58; 95% CI, .21–1.52; P = .27). In patients with severe sepsis, antituberculosis therapy was associated with an improved 28-day survival rate (log-rank test P = .01), and with a reduced mortality rate in a Cox proportional hazards model (hazard ratio, 0.32; 95% CI, .13–.80; P = .03). Conclusions: Empiric antituberculosis therapy was associated with improved survival rates among patients with severe sepsis, but not among all patients with sepsis.
Collections
- Research Articles [432]